A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH

Nirmatrelvir‐ritonavir (Paxlovid) is a brand‐new oral antiviral medication for treating mild to severe COVID‐19. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for ritonavir‐nirmatrelvir on December 22, 2021, to treat COVID‐19. We describe a case of mild COVID‐19...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Sarah, Reda Mostafa, Mostafa, Magdi Eid, Mohamed, AbdelQadir, Yossef Hassan, Abdelghafar, Yomna Ali, Swed, Sarya, Jahshan, Bishara, El‐Radi, Waddah Abd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465720/
https://www.ncbi.nlm.nih.gov/pubmed/37655131
http://dx.doi.org/10.1002/ccr3.7860
Descripción
Sumario:Nirmatrelvir‐ritonavir (Paxlovid) is a brand‐new oral antiviral medication for treating mild to severe COVID‐19. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for ritonavir‐nirmatrelvir on December 22, 2021, to treat COVID‐19. We describe a case of mild COVID‐19 infection who developed severe hyponatremia following the administration of Paxlovid. Clinical and laboratory evaluations suggest SIADH, likely secondary to Paxlovid. The potential side effects of this medication still require further study.

Ejemplares similares